This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n7http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/pubchem-substance/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/kegg-drug/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/drugbank/
n15http://linked.opendata.cz/resource/mesh/concept/
n13http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/chemspider/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/wikipedia/
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/pharmgkb/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB04570/identifier/pubchem-compound/
n21http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB04570
rdf:type
n3:Drug
n3:description
Broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections. [PubChem]
n3:generalReferences
# Weitekamp MR, Aber RC: Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 1983 Jan 7;249(1):69-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6217353 # Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M: Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986 Nov;146(11):2159-64. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3778044
n3:group
approved
n3:halfLife
1.6 hours
n3:indication
Latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins. It is used to treat bacterial infections. Latamoxef is primarily indicated in conditions like Bone and joint infection, GI infections, Gynecological infections, Meningitis, Respiratory tract infections, Septicaemia, Skin infections, Soft tissue infections, UTI.
owl:sameAs
n13:DB04570 n16:DB04570
dcterms:title
Latamoxef
adms:identifier
n6:47499 n7:46505546 n8:DB04570 n9:D08109 n10:599928 n11:43215 n17:PA164743144 n18:Latamoxef
n3:mechanismOfAction
Penicillins acylate the penicillin-sensitive transpeptidase C-terminal domain (the penicillin-binding protein) by opening the lactam ring. This inactivation of the enzyme prevents the formation of a cross-link of two linear peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that amoxicllin interferes with an autolysin inhibitor.
n3:routeOfElimination
Renal Excretion accounts for 75 %
n3:synonym
Oxa-cephem moxalactam Latamoxef Latamoxefum Lamoxactam LMOX
n3:toxicity
Latamoxef produces potentially life-threatening effects which include Bleeding, Hypothrombinemia, Platelet dysfunctioning. which are responsible for the discontinuation of Latamoxef therapy. The symptomatic adverse reactions produced by Latamoxef are more or less tolerable and if they become severe, they can be treated symptomatically, these include Diarrhea, Skin rashes, Hematuria, Hyperuricemia, Pyuria, Raised serum creatinine.
n3:volumeOfDistribution
8.51 L
n3:proteinBinding
40%
n14:hasConcept
n15:M0014142
n3:IUPAC-Name
n4:271B3F4C-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3F52-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3F51-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3F4E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3F4F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3F50-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3F4A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3F48-363D-11E5-9242-09173F13E4C5 n4:271B3F62-363D-11E5-9242-09173F13E4C5 n4:271B3F4B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3F49-363D-11E5-9242-09173F13E4C5
n20:hasATCCode
n21:J01DD06
n3:H-Bond-Acceptor-Count
n4:271B3F58-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3F59-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3F53-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3F54-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3F56-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3F55-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3F57-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed after oral administration.
n3:casRegistryNumber
64952-97-2
n3:category
n3:Bioavailability
n4:271B3F5E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3F60-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3F61-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3F5D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3F5C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3F5F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3F4D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B3F5A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3F5B-363D-11E5-9242-09173F13E4C5